United States Autoimmune Disease Diagnostics Market to Grow with a CAGR of 7.02% through 2029

Rising disease prevalence, government initiatives, and an expanding product portfolio is expected to drive the United States Autoimmune Disease Diagnostics Market growth in the forecast period, 2025-2029.

According to TechSci Research report, “United States Autoimmune Disease Diagnostics Market – By Region, Competition, Forecast and Opportunities, 2029F”, the United States Autoimmune Disease Diagnostics Market was valued at USD 1.45 billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.02% through 2029. Market growth can be largely attributed to collaborations and mergers within the healthcare sector. Companies often partner to leverage their expertise, share resources, and develop comprehensive diagnostic solutions. These collaborations lead to the creation of innovative diagnostics that effectively address the complexities of autoimmune diseases.

Additionally, the shift towards patient-centric diagnostics emphasizes the importance of the patient experience and preferences. This trend prioritizes communication, education, and shared decision-making between patients and healthcare providers. As autoimmune disease diagnostics evolve, they increasingly involve patients in the diagnostic process, fostering more informed decisions and enhancing adherence to treatment plans.

Several factors are driving this market, including the rising prevalence of autoimmune diseases, heightened awareness of disease diagnosis, and technological advancements. The increasing incidence of autoimmune disorders is expected to significantly boost the autoimmune disease diagnostics market. For instance, the 2020 Atlas of Multiple Sclerosis Report noted that over 2.8 million people globally, including approximately 1 million in the United States, are living with multiple sclerosis. Europe bears a substantial burden, with the highest prevalence of multiple sclerosis in 2020, affecting an estimated 2.5 million people worldwide. Additionally, rheumatoid arthritis impacts around two million individuals, and psoriasis, one of the most prevalent autoimmune disorders, is believed to affect 2% to 3% of the general population. Enhanced awareness of autoimmune disorders through research, education, and advocacy initiatives is a significant driver of increased diagnosis rates.

The growing global burden of autoimmune diseases, coupled with rising health and disease awareness, is fueling demand for early detection diagnostics, thus driving market growth. For example, the American Autoimmune Related Disease Association (AARDA) has designated March as Autoimmune Disease Awareness Month (ADAM) to raise awareness and support efforts to combat autoimmune diseases. Similarly, the American Kidney Fund (AKF) launched an educational campaign in February 2021 focused on lupus nephritis, providing vital information about symptoms, diagnosis, and treatment to patients. In September 2021, Scipher Medicine partnered with Ventegra Inc. to offer customers access to Scipher's PrismRA liquid molecular signature test, facilitating personalized treatment for rheumatoid arthritis patients.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "United States Autoimmune Disease Diagnostics Market.”

The United States Autoimmune Disease Diagnostics Market is segmented into component, test type, disease type, end user, regional distribution, and company.

Based on end user, hospitals and clinics are poised to dominate the United States autoimmune disease diagnostics market due to their pivotal role in healthcare infrastructure. These healthcare facilities serve as primary points of care for patients seeking diagnosis and treatment. With the increasing prevalence of autoimmune diseases and the need for accurate and timely diagnostics, hospitals and clinics become central hubs for autoimmune disease testing. They offer a wide range of diagnostic services, access to specialized medical professionals, and state-of-the-art equipment necessary for comprehensive autoimmune disease diagnosis. Moreover, the trend toward collaborative and multidisciplinary approaches to healthcare further solidifies the position of hospitals and clinics as key players in the autoimmune disease diagnostics market, as they provide integrated care and access to a wide array of diagnostic tools, including advanced imaging, genetic testing, and biomarker-based assays, essential for accurate diagnosis and effective disease management.

Based on region, The North-East region is exceptionally well-positioned to dominate the United States Autoimmune Disease Diagnostics market for several compelling reasons. It is home to some of the nation’s most prestigious academic and medical institutions, including Harvard, MIT, and Johns Hopkins, which are leaders in cutting-edge research and innovation in healthcare. These institutions attract top talent, resulting in a concentration of expertise in autoimmune disease diagnostics. The North-East's densely populated urban centers, such as Boston, New York, and Philadelphia, offer a diverse patient demographic that drives demand for advanced diagnostic solutions, enhancing the market's growth potential. The region also benefits from strong healthcare policies and comprehensive insurance coverage, ensuring that patients have access to state-of-the-art diagnostic technologies and services. The North-East's well-established biotechnology and pharmaceutical sectors promote collaboration and investment in autoimmune disease diagnostics, solidifying its status as a leader in this critical area of healthcare innovation.

Major companies operating in United States Autoimmune Disease Diagnostics Market are:

• Abbott Laboratories
• Siemens Healthineers AG
• Roche Diagnostics Corp
• Beckman Coulter Inc
• SQI Diagnostics Inc
• EUROIMMUN Medizinische Labordiagnostika AG
• Aesku Diagnostics GmbH & Co KG
• INOVA Diagnostics Inc
• Crescendo Bioscience LLC
• bioMerieux SA

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The United States Autoimmune Disease Diagnostics Market is witnessing a transformation driven by emerging trends that focus on precision medicine, biomarker discovery, point-of-care testing, artificial intelligence, telemedicine, multiplex testing, patient-centric diagnostics, global expansion, and ongoing research and development. These trends hold the promise of improving the accuracy, accessibility, and personalization of autoimmune disease diagnostics, ultimately enhancing patient care and outcomes. As technology continues to advance and the understanding of autoimmune diseases deepens, the future of autoimmune disease diagnostics appears promising, offering hope for better disease management and improved quality of life for patients”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“United States Autoimmune Disease Diagnostics Market By Component (Instruments, Reagents, Consumables), By Test Type (Routine Laboratory Tests, Inflammatory Markers, Antibodies & Immunologic Tests, Others), By Disease Type (Systemic Autoimmune Disease Diagnostics {Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Others}, Localized Autoimmune Disease Diagnostics {Multiple Sclerosis, Type 1 Diabetes, Hashimoto’s Thyroiditis, Others}), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By Region, By Competition, Forecast & Opportunities, 2019-2029F”, has evaluated the future growth potential of United States Autoimmune Disease Diagnostics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States Autoimmune Disease Diagnostics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com